Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. - Wikidata - wikimedia - TriplyDB

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

http://www.wikidata.org/entity/Q44032751

about

Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the l Musculoskeletal complications of haematological disease Management of endocrine disease: Secondary osteoporosis: pathophysiology and management The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Relationship between serum RANKL and RANKL in bone Computational modeling of interactions between multiple myeloma and the bone microenvironment Regulation of osteoclast differentiation Components of the RANK/RANKL/OPG system, IL-6, IL-8, IL-16, MMP-2, and calcitonin in the sera of patients with bone tumors.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.The effects of proteasome inhibitors on bone remodeling in multiple myeloma.Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.Novel therapeutic targets in myeloma bone disease.Bone disease in multiple myeloma: pathophysiology and management.Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease.Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment.Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.Antibody-based therapies in multiple myeloma New insights into the pathophysiology and management of bone disease in multiple myeloma.Targeting bone as a therapy for myeloma.Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis Myeloma bone disease: pathophysiology and management.Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.Advances in the management of myeloma bone disease.Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome.The effects of lung and prostate cancer bone metastasis on serum osteoprotegerin levels: a meta-analysis.Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males.Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Treatment strategies for bone disease.RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.Mechanisms of multiple myeloma bone disease.The pathogenesis of the bone disease of multiple myeloma.RANKL/RANK/OPG: key therapeutic target in bone oncology.A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease

P2860

Q26783464-80718796-863F-42BA-BDB3-111B8CFFF4EA Q26786755-81035776-EF59-4EE8-B204-DAA00A5C44FE Q26998249-741DBACF-FE8D-4775-8099-20F5A97A85DF Q28075927-A8238CE2-AC14-4F4A-87BD-63EA01D77EFC Q28082335-4F3135FB-EB13-4075-8105-9047FCE8F340 Q28245828-C62BC2A9-649B-4EFE-BADC-4ADE71DC0F6B Q28477867-D99D7934-6A07-4479-A276-B76F6F51F3B6 Q28593319-C97500E6-22DF-434E-BC0F-B559A0CADEEC Q33275358-71BBA941-4898-46FE-A79D-B97A5EDC0F64 Q33564854-47769E62-6361-45E2-A20D-65AEB6AB6B5B Q33918020-47C48BD5-F114-452D-94C3-C24ED1F8240E Q33953955-B7378333-230C-4B03-BCD0-99FA6357614C Q34025065-A06B08B3-768D-4D05-BCD0-EE93ED9615CE Q34045789-97069874-4CB5-4440-8467-FE9D3C8FC9B4 Q34404651-A3E63E66-2046-4988-9D8E-B36CFEECEEB8 Q34806153-072568D0-1C46-4CD5-B382-48E36FFC63E0 Q34960867-77D1E19C-8858-4B20-9120-1F73B5CDB011 Q35220234-D5AD5CB8-114B-477B-AC08-42F21D4E2ABC Q35422468-E1CBAFC3-35D3-4DB1-9668-735BE43A55A3 Q35431150-B4067883-BE17-4A64-B71A-BE7FA30AF200 Q35591086-57D041CC-10DF-4CDD-BCF3-0A90640E9470 Q35603128-E4177C95-8C25-4054-BF38-98A720067A27 Q35769514-B3A2A64C-BB3D-4B2A-8C2F-4BD37556FDCC Q35843398-2C16A67C-7080-4C6D-AC46-CA91327B27C1 Q36146493-41E82522-27C0-46F6-9A3C-F47B14687783 Q36288753-46D2F2A5-6627-487E-B72F-372EB7294D9A Q36303451-F8415895-71F0-468A-887D-59CD0A0724F0 Q36327078-E2925DAC-8709-44AC-8280-502A72E3A1C3 Q36366608-5C1B8D13-44BA-49B3-9F85-5969DE1CA885 Q36376105-7CEFDD22-C1C5-496A-A9F2-B0561F9F822D Q36641523-91906BEB-EEA7-49D9-813E-F9A32BA9E037 Q36732811-E9F21FBD-B716-4CD9-AA10-EAB5A82D81D7 Q36816063-CA05619E-64EC-44EE-BD4F-3C66BDF396F9 Q36860987-01CF031C-094E-4D17-B418-C1D79355C839 Q36902828-A51E773F-4B4E-4B70-8558-CF3867D0C483 Q37007044-A2883C92-8CD1-480F-9EF2-122A48E2B3EE Q37056408-75014A09-E25D-4410-A1AF-B1946A45EC4C Q37136324-F2AF1AAC-25D7-4D28-97A5-CE11080F9580 Q37140665-DA6046DF-8A98-43BA-88CE-72D358DF16F5 Q37185494-8163700D-A45C-4CD1-AD21-F5B6D245ECFB

P2860

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

http://www.wikidata.org/entity/Q44032751

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh

2003年學術文章

@zh-hant

name

Soluble receptor activator of ...... for a novel prognostic index.

@en

Soluble receptor activator of ...... for a novel prognostic index.

@nl

type

label

Soluble receptor activator of ...... for a novel prognostic index.

@en

Soluble receptor activator of ...... for a novel prognostic index.

@nl

prefLabel

Soluble receptor activator of ...... for a novel prognostic index.

@en

Soluble receptor activator of ...... for a novel prognostic index.

@nl

P1433

Q44032751-687E707D-9BCC-4CE6-86D0-05E7FC5BF54D

P1476

Q44032751-1DD9B21B-F778-4947-BD99-757C954EF715

P2093

Q44032751-134DAF14-3748-4992-AD8F-B44C1262B72E

Q44032751-2E2660B1-E196-471B-A428-7161E0E6BEE1

Q44032751-77010BF0-0FE2-4D24-9BC8-D457DDE7222D

Q44032751-891634CE-03A4-4ED9-AAEE-AAFC5874496E

Q44032751-94E91251-3E01-4FA0-9F86-42A522484E23

Q44032751-9C7D304F-27F5-4211-8F3A-C50B59EA8B77

Q44032751-D5C98B41-A4A9-46BD-B04B-B80D1F53C5EE

Q44032751-E37FF7E1-4457-4107-8AFD-5EC7CB1FCC23

Q44032751-E58D4D5B-BB65-4436-B5B4-51E91CE0C0C5

P304

Q44032751-06DC6301-E9D8-4C2C-943C-494DCD5F3F03

P31

Q44032751-35C128D5-A30C-42AF-9401-60C80AEC147C

P356

Q44032751-23D952DE-6382-47B7-AE82-357FB144B140

P407

Q44032751-3C2B1FCB-27DA-4BD5-8A3B-9579683EE32C

P433

Q44032751-6B9D31AB-9E16-44BC-AFDD-571D118A1DC3

P478

Q44032751-A639F5E8-8B85-4A53-BA6C-63B22A1D3317

P50

Q44032751-35060864-3A8F-4EF3-A6E8-4E9B32E353C4

P577

Q44032751-B0C372F3-BA57-4443-AC05-50ADA2485EE4

P5875

Q44032751-9BF48FD9-0568-46AE-8399-85832F04C8A0

P698

Q44032751-61348062-FB01-4C76-BE0C-F068E1F73BE1

P356

BLOOD-2003-02-0380

P1433

P1476

Soluble receptor activator of ...... for a novel prognostic index.

@en

P2093

Amin Rahemtulla

http://www.w3.org/2001/XMLSchema#string

Evangelos Terpos

http://www.w3.org/2001/XMLSchema#string

Evdoxia Hatjiharissi

http://www.w3.org/2001/XMLSchema#string

Jane F Apperley

http://www.w3.org/2001/XMLSchema#string

John M Goldman

http://www.w3.org/2001/XMLSchema#string

John Meletis

http://www.w3.org/2001/XMLSchema#string

Marianna Politou

http://www.w3.org/2001/XMLSchema#string

Nora Viniou

http://www.w3.org/2001/XMLSchema#string

Xenophon Yataganas

http://www.w3.org/2001/XMLSchema#string

P304

1064-1069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2003-02-0380

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-04-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10809555

http://www.w3.org/2001/XMLSchema#string

P698

12689925

http://www.w3.org/2001/XMLSchema#string